Nevertheless, in a potential clinical trial, investigating EPO treatment for improving outcome of severe COVID-19 patients (Ehrenreich et al. 2020), and particularly for preventing neuroCOVID and long COVID (Llach and Vieta 2021), at least 10× higher doses may have to be tested—perhaps as parallel study arm—to disclose the optimal amount required for these conditions. This evidence concerns the gene EPO and COVID-19.